- TRADE NAME: Tabrecta (Novartis)
- INDICATIONS:
Metastatic non-small cell lung cancer in adult patients.
NOTE: (2020) FDA approved under accelerated approval based on overall response rate and duration of response. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
- SYNONYM: Capmatinib hydrochloride
- CLASS: Kinase inhibitor, MET (mesenchymal-epithelial transition) inhibitor / MET tyrosine kinase inhibitor
- HALF-LIFE: 6.5 hours
- FDA APPROVAL DATE: 05/06/2020
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP3A inducers, CYP3A inhibitors, Itraconazole, Rabeprazole, Rifampin - PREGNANCY: Can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception.
- See adverse reactions attributed to class:
MET (mesenchymal-epithelial transition) inhibitor / MET tyrosine kinase inhibitor
Please login to view the rest of this drug profile.
Page last updated 08/21/2024
